Nvidia Invests $10.4 Million in AI Biotech Company Generate Biomedicines

Nvidia has invested approximately $10.4 million in clinical-stage biotech company Generate Biomedicines (GENB), acquiring a stake valued at around 833,325 shares based on its latest 13F filing. While the investment is relatively small for Nvidia given its scale, it could signal confidence and support for GENB's AI-driven drug development approach.

By Sushree Mohanty Wed, May 20, 2026 at 10:45 PM GMT+3 4 min read · Yahoo Finance · May 20, 2026, 19:45 UTC

Tickers: $GENB $NVDA

Topics: AI biotech Nvidia investment

Read the full article at Yahoo Finance

More World news

Cohen & Company Appoints Daniel Cohen as CEO with $500 Million Revenue Target Seeking Alpha · November 12, 2026, 19:10 UTC
X-Energy Receives Early NRC Construction Permit and Anticipates Dow Investment Decision by 2027 Seeking Alpha · November 12, 2026, 19:10 UTC
Alvotech Shares Decline Following Third Quarter Earnings Miss Seeking Alpha · November 12, 2026, 19:05 UTC
Saga Communications Projects $5.7 Million in 2026 Political Revenue Amid Q4 Growth Seeking Alpha · November 12, 2026, 19:00 UTC
Corteva Forecasts 2026 Operating EBITDA Between $1.1B and $1.125B Amid Brazilian Market Pressures Seeking Alpha · November 12, 2026, 19:00 UTC
DPC Holdings PLC Reports Record Q3 Revenue Growth and Issues 2027 Financial Guidance Seeking Alpha · November 12, 2026, 19:01 UTC
Senate Minority Leader Schumer Demands Congressional Testimony from Nvidia Following Jensen Huang's Resignation The Verge · November 12, 2026, 18:59 UTC
Nvidia Shares Plunge Following CEO Jensen Huang's Departure Amid Investigation Motley Fool · November 12, 2026, 19:00 UTC
San Francisco Fed President Mary Daly Views AI as Transformative Investment Opportunity Seeking Alpha · November 12, 2026, 19:00 UTC
Jensen Huang Resigns as Nvidia CEO Amid Personal Conduct Controversies and China Export Investigations Motley Fool · November 12, 2026, 18:56 UTC